Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Assets (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Non-Current Assets for 10 consecutive years, with $45.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 51.14% year-over-year to $45.0 million, compared with a TTM value of $250.6 million through Sep 2025, down 28.29%, and an annual FY2024 reading of $13.4 million, down 84.31% over the prior year.
  • Non-Current Assets was $45.0 million for Q3 2025 at Zevra Therapeutics, up from $29.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $92.1 million in Q3 2024 and bottomed at -$87.9 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $18.5 million, with a median of $13.4 million recorded in 2024.
  • The sharpest move saw Non-Current Assets tumbled 3458.6% in 2022, then surged 4577.96% in 2024.
  • Year by year, Non-Current Assets stood at $17.9 million in 2021, then grew by 25.84% to $22.5 million in 2022, then surged by 279.41% to $85.4 million in 2023, then crashed by 84.31% to $13.4 million in 2024, then soared by 235.83% to $45.0 million in 2025.
  • Business Quant data shows Non-Current Assets for ZVRA at $45.0 million in Q3 2025, $29.9 million in Q2 2025, and $12.3 million in Q1 2025.